Irbegen Plus

Hydrochlorothiazide / Irbesartan, the active ingredient in Irbegen Plus, is an angiotensin II receptor blocker and thiazide diuretic presented as an oral tablet for oral use. It is used to lower high blood pressure in adult patients with hypertension. The combination therapy exploits complementary mechanisms to improve blood pressure control and reduce cardiovascular risk.

GNH USA supplies Irbegen Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent product quality and regulatory compliance across multiple regions.

Irbegen Plus, a combination antihypertensive, acts on the renin‑angiotensin system and renal sodium handling to manage hypertension.

Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. Diabetes‑related hypertension: helps control blood pressure and proteinuria in patients with type 2 diabetes. Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction by maintaining target blood pressure levels.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache or mild fatigue. - Increased urination or nocturia. - Electrolyte disturbances such as low potassium or sodium. - Mild gastrointestinal discomfort, including nausea. - Transient rise in blood glucose levels.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance requiring medical attention. - Hyperkalemia, particularly when used with potassium‑sparing agents. - Angioedema or swelling of the face, lips, or throat. - Acute kidney injury or significant rise in serum creatinine. - Severe hypotension leading to syncope. - Pancreatitis or severe allergic reactions.

Before initiating therapy, clinicians should assess baseline blood pressure, renal function, and electrolyte status.

Monitor blood pressure regularly: adjust therapy if target levels are not achieved. Check electrolytes and renal function: repeat labs within 1–2 weeks after starting. Avoid use in severe renal impairment: dose adjustment may be required. Use caution in hepatic disease: monitor liver enzymes if clinically indicated. Pregnancy and lactation: safety not established; avoid unless clearly needed. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbegen Plus may interact with several medicines that affect blood pressure, electrolytes, or renal function.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment. - Potassium supplements or potassium‑sparing diuretics (risk of hyperkalemia). - Lithium (increased lithium levels and toxicity). - NSAIDs (may reduce antihypertensive effect and impair renal function). - ACE inhibitors or other ARBs (excessive potassium rise).

Moderate Interactions (Monitor Closely): - Other antihypertensives (additive blood pressure lowering). - Diuretics (enhanced electrolyte loss). - CYP2C9 inhibitors such as fluconazole (may increase irbesartan levels). - Antidiabetic agents (possible need for dose adjustment). - Antacids containing aluminum or magnesium (may affect absorption).